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Obesity is a major cause of  morbidity and mortality worldwide and is 
common in adults and children. It arises as a result of  a prolonged energy 
imbalance within an obesogenic environment, especially in genetically sus-
ceptible individuals. Lifestyle weight management is the cornerstone of  treat-
ment, including diet, physical activity, and behaviour change. Multicomponent 
interventions have been demonstrated to result in modest weight loss, 
which can be increased further by the addition of  adjunct pharmacotherapy. 
Bariatric surgery has the greatest impact on weight loss and co- morbidities 
but is associated with the greatest risk of  complications. Whatever treatment 
is used, lifelong vigilance to prevent weight regain is required. Prevention of  
excess weight gain is key, using multi- sectoral public health approaches.
Definition
Obesity is a disease characterized by excessive body fat accumulation with 
multiple organ- specific consequences and is most commonly diagnosed in 
adults using body mass index (BMI). Individuals are classified according to their 
risk of  metabolic complications associated with excess weight (table 21.1).
although BMI is commonly used and useful at a population level, it is an 
indirect measure of  body fatness that cannot distinguish between different 
tissue types, nor does it describe the health risks associated with fat distri-
bution (see E Chapter 4, ‘Body mass index’). BMI alone should be used 
with caution; ideally measures of  fat distribution such as waist circumfer-
ence (WC) should also be used, although at BMI >35 kg/ m2, WC does not 
improve prediction of  co- morbidities.
WC is a single simple measurement and is a good indicator of  intra- 
abdominal fat deposition, which is associated with adverse health conse-
quences. Using WC (measured at the midpoint between the lower border 
of  the ribcage and the iliac crest), the following cut- off points have been 
described (table 21.2).
BMI and WC cut- offs for different populations
Different populations vary in their risk of  metabolic abnormalities and 
population- specific WC cut- off points have been defined (table 21.3).
Individuals of  south asian origin (Bangladeshi, Indian, and Pakistani origin) 
have greater prevalence of  metabolic abnormalities at lower BMI than 
would be expected and it has been proposed that for these populations, 
lower cut- off points for public health action should be used.
although there is a lack of  UK- based evidence for ethnicity- specific cut- off 
points, because of  increased risks at lower BMI (<25 kg/ m2) experienced by 
members of  black, asian, and other ethnic groups, it is recommended that 
the lower cut- off points of  23.0 kg/ m2 for increased risk and 27.5 kg/ m2 
for high risk are used to indicate need for action to prevent type 2 diabetes.
Other measures, such as waist- to- height ratio, are useful predictors of  
metabolic risk1 but less well understood by most healthcare professionals. 
More complex measures of  body composition, such as bioimpedance, are 
not recommended as alternatives to BMI in clinical practice.
1 ashwell, M., Gibson, S. (2016). Waist to height ratio as an indicator of  ‘early health risk’: simpler 
and more predictive than using a ‘matrix’ based on BMI and waist and circumference BMJ Open 6(3), 
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Table 21.1 Classification of weight using body mass index*
BMI range, kg/ m2 Classification Risk of co- morbidities
<18.5 Underweight Low (but may be other 
health problems)
18.5- 24.9 healthy weight average
25.0- 29.9 Overweight Increased
30.0- 34.9 Obesity I Moderate
35.0- 39.9 Obesity II Severe
≥40.0 Obesity III very severe
*reproduced with permission from World health Organization (WhO). Obesity: preventing and 
managing the global epidemic. WHO Technical Report Series 894. Geneva, Switzerland: World 
health Organization. Copyright © 2000 WhO M http:// www.who.int/ nutrition/ publications/ 
obesity/ WhO_ trS_ 894/ en/ .
Table 21.2 Cut- off points for risk of metabolic complications 
in Caucasian adults with obesity according to waist circumference*
Risk of metabolic complications Waist circumference, cm
Men Women
Increased ≥94 ≥80
Substantially increased ≥102 ≥88
*Source: data from ashwell, M., Gibson, S. (2016). Waist to height ratio as an indicator of  
‘early health risk’: simpler and more predictive than using a ‘matrix’ based on BMI and waist and 
circumference BMJ Open 14, 6(3):e010159. doi: 10.1136/ bmjopen- 2015- 010159.
Table 21.3 Waist circumference cut- off points according to ethnicity*
Population Gender WC in cm (inches)
european Men ≥94 (37)
Women ≥80 (31.5)




ethnic south and central 
americans
Use South asian recommendations in lieu of  more 
specific data
Sub- Saharan africans Use european recommendations in lieu of  
more specific data
*reproduced with permission from alberti, K.G.M.M., et al. International Diabetes Federation: a 










Obesity is a global public health problem affecting both adults and children 
in low and middle income as well as high income countries. In 2014, 39% of  
adults globally were overweight and of  those 13% were classed as obese.2 
this represents more than 1.9 billion adults being at least overweight, of  
whom more than 600 million were obese (266 million men and 375 million 
women).3 a recent study reported that overweight and obesity has doubled 
in more than 70 countries since 1980 and increased steadily in almost all 
other countries.4
UK
Prevalence of  excess weight in england increased by 72% between 1989 
and 2013, and prevalence of  obesity among adults rose from 15% to 27% 
between 1993 and 2015.5 Within the UK, 63% of  adults were classed as 
overweight or obese in 2015 (68% men and 58% women).
By 2050 obesity is predicted to affect 60% of  adult men, 50% of  adult 
women, and 25% of  children. Prevalence in the UK is comparatively 
high and ranked 8th for obesity prevalence in men (25.7%) and 11th for 
women (26.6%) out of  23 Organisation for economic Co- operation and 
Development (OeCD) countries in 2016.6
Who is at risk?
Major demographic risk factors for obesity include age, gender, ethnicity, 
and socioeconomic status. Prevalence of  obesity is generally higher in older 
than younger adults, except for oldest adults. the relationship between eth-
nicity and obesity prevalence is complex and varies with gender and method 
of  assessing obesity. Prevalence of  overweight and obesity is higher in men 
than women (68% and 58%, respectively, in the UK in 2015);7 however, the 
prevalence of  obesity was similar in both genders. an inverse relationship 
between socio- economic status and excess weight is seen in women but 
not men.
AQ: Note 2, please 
check web address as I 
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2 WhO. (2016). Obesity and overweight. Fact sheet 311. available at: M http:// www.who.int/ 
mediacentre/ factsheets/ fs311/ en/ .
3 NCD risk Factor Collaboration (NCDrisC) (2016). trends in adult body- mass index in 200 coun-
tries from 1975 to 2014:  a pooled analysis of  1698 population- based measurement studies with 
19.2 million participants. Lancet 387, 1377– 96.
4 GBD 2015 Obesity Collaborators (2017). health effects of  overweight and obesity in 195 coun-
tries over 25 years. N. Engl. J. Med. 377, 13– 27. available at: M http:// www.nejm.org/ doi/ full/ 
10.1056/ NeJMoa1614362.
5 Ng, M., et al. (2014). Global, regional and national prevalence of  overweight and obesity in children 
and adults during 1980- 2013: a systematic analysis for the Global Burden of  Disease Study 2013. 
Lancet 384, 766– 81.
6 OeCD (2018). health statistics 2018, frequently requested data. available at: M http:// www.
oecd.org/ health/ health- data.htm.
7 hSCIC (2015). Statistics on Obesity, Diet and Physical Activity. health and Social Care Information 
Centre, London. available at: M http:// www.content.digital.nhs.uk/ catalogue/ PUB16988/ obes- 














Obesity arises in genetically susceptible individuals exposed to obesogenic 
environments. as such it can be viewed as a normal response to an ab-
normal environment. the genetic heritability of  BMI is estimated to range 
from 40% to 70%,8 and there are numerous potential mechanisms through 
which genes may mediate effects on body weight, e.g. on appetite, food and 
activity preferences.
however, the rapid increase in prevalence globally indicates that social 
and environmental factors are also important. Factors favouring weight 
gain include increased consumption of  energy dense, nutrient- poor foods 
often in large portion sizes, reduced physical activity and increased time 
spent in sedentary activities, inadequate and/ or disturbed sleep, and stress. 
the roles of  prenatal influences, epigenetics and the gut microbiome have 
also received attention. Food prices and time cost of  fast foods, marketing 
and advertising, fast food consumption, and related behaviours may also 
contribute. that obesity is caused by numerous physical, biological/ physio-
logical, environmental, societal (cultural and economic), and psychological 
factors which interact in a complex matrix appears to be beyond doubt,9 
and action across all sectors is required to address this. See E Chapter 18, 
‘Obesity prevention’.
Co- morbidities and costs of obesity
high BMI is the third highest contributor to disease burden expressed as a 
percentage of  UK disability- adjusted life- years, after smoking and high blood 
pressure. BMI has been shown to strongly predict overall mortality; life ex-
pectancy both above and below the optimal 22.5kg/ m2 is comparatively 
reduced. reductions of  2- 4 years for BMI category 30- 35 kg/ m2, and 8- 
10 years for BMI category 40- 50kg/ m2 are estimated.
Co- morbidities include:
Metabolic: type 2 diabetes, cardiovascular disease, hypertension, hyperlip-
idaemia, some types of  cancer, increased risk of  liver and kidney disease, 
dementia, and reduced fertility as well as adverse outcomes of  pregnancy, 
gallstones, stroke, and polycystic ovary syndrome.
Physical: osteoarthritis, sleep apnoea, back pain, poor mobility, and in-
creased risk of  accidents.
Psychosocial: low self- esteem, poor body image, and depression. Obesity 
is a highly stigmatized condition, perhaps the only remaining socially accept-
able stigma. Stigma and bias can result in worse treatment outcomes, poor 
adherence to treatment plans, and reluctance to seek help.
Financial impact of  obesity includes direct and indirect costs such as lost 
productivity, welfare payments, and increased morbidity and mortality. 
additional hidden costs of  obesity include increased fuel required for 
greater food production and transport of  heavier people, increasing green-
house emissions and carbon footprint.
AQ: Please update 
page number on 
proofs
8 herrera, B.M., et al.(2011). Genetics and epigenetics of  obesity Maturitas 69, 41– 9.
9 Foresight (2007). Obesity Systems Map. available at: M https:// www.gov.uk/ government/ up-












a thorough assessment to develop a tailored individualized care plan is fun-
damental to good practice. Suggested areas for assessment are shown in 
table 21.4. Weight should not be the sole focus of  either assessment or 
treatment; feasible healthy changes to behaviours, improving diet and ac-
tivity levels, will increase the likelihood that changes will be sustained.




 • Body mass index;
 • Waist circumference.
B. Medical
 • Potential causes, e.g. endocrine, neurological, medications, genetic 
influences (age of  onset, family history);
 • Co- morbidities: current and future risk;
 • Severity of  obesity and extent of  physical disability.
C. Psychological
 • Identify psychological factors, e.g. depression, addictive behaviours;
 • Eating disorders: binge eating, bulimia nervosa, disordered eating;
 • Risk of  potential barriers to treatment, e.g. psychiatric history.
D. Nutritional
 • Weight history: extremes of  adult weight, patterns of  weight gain and 
loss, age of  onset, triggers to weight gain, triggers to disordered or 
excessive eating;
 • Dieting history: number and types of  diet, weight loss medications, 
success of  previous attempts to manage weight, alternative or 
complementary approaches to weight management;
 • Current eating patterns: meal patterns (meals skipped, snack 
consumption, largest meal eaten);
 • Nutritional intake: nutrient density, nutritional supplements;
 • Environmental factors: meals eaten away from home, fast food 
consumption, restaurant meals, ethnic foods, lifestyle factors (time, 
financial);
 • Exercise history: current exercise, activities of  daily living, exercise 
history, barriers to exercise;
 • Readiness to change: reasons to lose weight, weight loss goals, support 
systems, likely difficulties, readiness for making changes.
*Source: data from american Dietetic association (2009). Position of  the american Dietetic 








First line treatment is lifestyle intervention to change eating and activity be-
haviours and achieve negative energy balance and weight loss. Modification 
of  the eatwell Guide may be used10 (see E Chapter 2), although this may 
be too unstructured an approach for those who struggle with portion size.
the aim of  treatment is usually loss of  5- 10% of  initial body weight 
although this should relate to initial body weight, so those with a BMI 
<40  kg/ m2 may aim for 5% and those with BMI of  >40  kg/ m2 aim for 
>10%. Weight loss at this level is achievable, sustainable, and incurs signifi-
cant clinical benefit. the majority of  weight loss occurs in the first 6 months, 
with weight regain thereafter in most individuals. Multicomponent interven-
tions (i.e. those tackling diet, physical activity, and behaviour change) are 
recommended.
10 Public health england. (2016). eatwell Guide. available at: M https:// www.gov.uk/ government/ 
publications/ the- eatwell- guide.
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the ideal macronutrient composition of  a weight loss diet is hotly con-
tested, and a variety of  approaches have been shown to result in modest 
weight losses in the short term. Studies lasting longer than a year typically 
do not show significant weight differences between different dietary groups, 
either in terms of  weight lost or weight loss that is maintained. adherence 
to weight management interventions in the long term is critical to success. 
Modest weight losses at the individual level have the potential for a large 
impact on public health. this suggests that so long as a hypocaloric weight 
loss diet is otherwise nutritionally complete, individual preferences can dic-
tate the type of  diet followed, and may help improve adherence to the 
programme.
there is evidence to support a range of  dietary approaches resulting in 
moderate weight loss of  approximately 5- 8.5 kg (5- 9%) in the first 6 months. 
these include an energy- restricted diet (generally 500- 600 kcal below re-
quirements), a low fat diet (<30% energy from fat), and meal replacements. 
this modest effect may reduce adherence to diets and expectations both 
of  patients and commissioners must be addressed to reduce this possibility.
Low carbohydrate
Low carbohydrate diets appear to result in modestly greater weight loss 
compared with low fat diets. Systematic reviews11,12 found that low carbo-
hydrate diets (≤120 g/ day and ≤60 g/ day, respectively) resulted in signifi-
cantly greater weight loss and improved lipid profiles compared with low fat 
diets (≤30% energy from fat) and low energy diets (600 kcal deficit diet).
however, the long- term safety of  low carbohydrate diets is unclear. 
Studies using low carbohydrate diets are heterogeneous, using different in-
clusion criteria, different levels of  carbohydrate restriction, different study 
durations and follow- up, all of  which may affect assessment of  their clinical 
value. additionally, many studies do not include intention- to- treat analysis, 
thus possibly overestimating their benefits.
Low GI/ GL
Studies of  low glycaemic index (GI) and glycaemic load (GL) tend to be 
small and heterogeneous. a  systematic review13 concluded that low GI 
diets resulted in significantly greater weight loss and improved risk factors 
when compared with other diets. even ad libitum low GI diets were at least 
as good as conventional energy restricted diets. however, only six small 
studies were included, duration of  studies was short, ranging from 5 weeks 
to 6 months, and only two studies included obese adults. they are gener-
ally not recommended as a sole dietary management approach because of  
11 Sackner- Bernstein, J., et al. (2015). Dietary intervention for overweight and obese adults: com-
parison of  low- carbohydrate and low- fat diets. a meta- analysis. PLoS One 10, e0139817.
12 Noto h., et al. (2012). Low- carbohydrate diets and all- cause mortality: a systematic review and 
meta- analysis of  observational studies. PLoS One 8, e55030.
13 thomas D., et al. (2007). Low glycaemic index or low glycaemic load diets for overweight and 





med-9780198800132-chapter-21.indd   478 02-Dec-19   15:22:47
WeIGht MaNaGeMeNt: DIetary aPPrOaCheS 479
  
a lack of  well- controlled long- term studies. however, in those with insulin 
sensitivity or resistance, hypocaloric low GI/ GL diets may be preferred and 
if  they suit personal preference and are of  adequate nutritional quality they 
may be a useful strategy for some individuals.
Intermittent fasting
Intermittent fasting or intermittent energy restriction (Ier)14,15 can take 
a number of  forms, but is defined as periods of  energy restriction inter-
spersed with normal energy intake. Studies have shown that Ier approaches 
result in similar weight loss to interventions using continuous energy restric-
tion, but a variety of  different approaches to Ier are used and many studies 
are short term. Weight loss outcomes in Ier compared with continuous 
restriction for a minimum of  6 months do not differ significantly. Longer- 
term effects of  Ier, particularly if  non- restricted days are used to either fast 
or feast are unclear. therapeutic fasting practised too often or for too long 
may have negative effects. the approach has potential value for overweight 
or obese individuals who find continuous restriction difficult, because an 
intermittent approach means that usual intake can be consumed on non- 
restricted days, and Ier was not shown to result in adaptive responses to 
restricted energy intake. there is some evidence that Ier improves some 
aspects of  mental health in overweight or obese individuals, but more re-
search is needed using sufficiently powered studies to identify optimal Ier 
patterns, whether there are differences in body composition between con-
tinuous restriction and Ier and whether there are differential effects in men 
compared to women using this approach. In addition, potential longer- term 
effects, both positive and negative, need to be identified.
Meal replacements
these portion- controlled products supplemented with vitamins and min-
erals are designed to replace one to two meals per day, with one remaining 
meal using conventional foods, and an overall aim of  achieving intakes of  
1200- 1600 kcal/ day. they have been shown to be beneficial in short- and 
long- term use, in primary care and unsupervised ‘off- the- shelf ’ use. a role 
in weight maintenance has also been demonstrated. For example, in the 
Look aheaD trial,16 weight loss of  4.7% at 8 years in the intervention arm 
was seen. Meal replacements were one of  the dietary strategies used in 
both the weight loss and maintenance phases of  this trial involving 5145 
ethnically diverse adults with type 2 diabetes. For those who have diffi-
culty with portion control or food selection, they may be a useful strategy 
for both weight loss and weight maintenance.12 Because they are neither 
14 harvie, M., et al. (2017). Potential benefits and harms of  intermittent energy restriction and inter-
mittent fasting amongst obese, overweight and normal weight subjects – a narrative review of  human 
and animal evidence. Behav. Sci. 7, pii.e4. DOI: 10.3390/ bs7010004.
15 horne, B.D., et al. (2015). health effects of  intermittent fasting: hormesis or harm? a systematic 
review. Am. J. Clin. Nutr. 102, 464– 72.
16 LookaheaD research Group. (2014). eight- year weight losses with an intensive lifestyle inter-
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extreme dietary approaches nor total diet replacements, they can be used 
indefinitely.
Very low energy diets
very low energy diets (vLeD) or very low calorie diets (vLCD) are com-
plete dietary replacements, providing 450- 800 kcal/ day, and are nutrition-
ally complete apart from energy. they can be used for a maximum of  12 
weeks continuously or intermittently as part of  a comprehensive strategy 
with ongoing clinical support and should not be routinely used to manage 
obesity. the use of  vLeD has been shown to result in rapid substantial 
weight loss followed by rapid weight regain. they may be useful in situ-
ations where rapid weight loss is needed under clinical supervision and with 
a planned reintroduction of  conventional foods.
Over >6  months, there appears to be little difference in the weight 
loss achieved by following diets differing in macronutrient composition. 
adherence to the diet is what counts and what predicts weight loss, and 
this seems to be more important than the exact macronutrient breakdown. 
Part of  a tailored approach may be modifying diets in terms of  their macro-
nutrient composition depending on the preferences and health status of  the 
individual; with the proviso that the nutritional quality of  the diet is a critical 
consideration.
Potential concerns associated with vLeD include malnutrition and keto-
acidosis but these were not identified as adverse effects by a recent sys-
tematic review.17
17 Parretti, h.M., et al. (2016). Clinical effectiveness of  very- low- energy diets in the management 












Physical activity alone is less effective in bringing about weight loss than 
diet and physical activity combined.18 regardless of  its impact on weight, 
physical activity should always be recommended because of  its beneficial 
effects on health and wellbeing. It is also thought to be a critical factor in 
weight maintenance. those who successfully lost 10% body weight and kept 
it off at 24 months follow- up spent more time being physically active than 
those who did not. Successful weight loss maintainers report daily physical 
activity, both planned and activities of  daily living, and this may be the key 
to their success.
18 Johns, D.L., et al. (2014) Diet or exercise interventions vs combined behavioural weight man-
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Multicomponent interventions including diet, physical activity, and behav-
iour change are more effective than either diet or activity alone.
Current UK guidance19 suggests that the following strategies should be 
included in behavioural interventions for adults, as appropriate:
 • self- monitoring of  behaviour and progress;
 • stimulus control;
 • goal setting;
 • slowing rate of  eating;
 • ensuring social support;
 • problem solving;
 • assertiveness;
 • cognitive restructuring (modifying thoughts);
 • reinforcement of  changes;
 • relapse prevention;
 • strategies for dealing with weight regain.
19 National Institute for health and Care excellence (NICe). (2014). Obesity:  identification, assess-
ment and management. Clinical guideline 189. available at: M https:// www.nice.org.uk/ guidance/ 
cg189/ chapter/ 1- recommendations#identification- and- classification- of- overweight- and- obesity.
C21.S8
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Currently only one medication, orlistat (brand names include Xenical and 
alli) is licensed for use in the UK. Orlistat is a pancreatic lipase inhibitor 
which reduces absorption of  dietary fat by approximately 30% when given 
with a diet comprising approximately 30% fat. Used in combination with 
lifestyle change, weight loss of  2.9 kg greater than placebo was observed. 
Orlistat is not well absorbed so systemic side effects are minimal; the lar-
gest problems relate to unabsorbed dietary fat until patients learn to re-
duce their dietary fat intakes. there may be some reduced absorption of  
fat- soluble vitamins and reduced absorption of  the drug acyclovir. Severe 
adverse effects are very rare but may include acute kidney injury so orlistat 
should be used with caution in renal impairment.
Current guidance in the UK:22
 • Prescribe for adults with a BMI of  ≥28 kg/ m2 plus co- morbidity or BMI 
≥30 kg/ m2 as part of  a plan to manage obesity.
 • Continued prescribing should only occur in those who have lost at least 
5% of  their initial body weight, although lower targets may be set for 
those with type 2 diabetes, in whom weight loss tends to be lower.
 • Supplements are generally not considered necessary unless orlistat is 
used in vulnerable groups, e.g. young people.
Sibutramine, an appetite suppressant, was withdrawn from licence for 
treating obesity in the UK in 2010 and in several other countries including the 
european Union, India, and USa because of  associated cardiovascular risks. 
Other appetite suppressants, including dexfenfluramine and rimonabant, 
have had approval withdrawn because of  health risks exceeding possible 
benefits. however, unlicensed drugs are available to purchase online so 
health professionals need to be aware of  the risks associated.
Drugs that aim to promote satiety via gastrointestinal effects, e.g. methyl 
cellulose and sterculia, are not recommended because of  lack of  evidence 
that they are effective.
Ongoing obesity pharmacology development indicates that new drugs 
may become available in the near future.20












Bariatric surgery is the most effective intervention for achieving weight loss 
in obese adults,21 but has more complications than non- surgical methods. 
all types of  bariatric surgery are associated with significantly greater re-
mission of  diabetes compared with controls at 10 years and 15 years post- 
surgery, and significant improvements to weight- related complications.
Current UK guidance22 recommends bariatric surgery:
 • as first line treatment in those with BMI ≥50 kg/ m2 in whom other 
interventions have failed;
 • as a treatment option in those with BMI ≥40 kg/ m2 or between 35 and 
40 kg/ m2 and significant disease that would benefit from weight loss;
 • all appropriate non- surgical measures have been tried but adequate 
weight loss has not occurred or been maintained;
 • patients receiving intensive management in a tier 3 service;
 • patients generally fit for anaesthesia and surgery;
 • committed to need for long- term follow- up;
 • expedited referral to bariatric surgery should be offered to those with 
BMI ≥35 kg/ m2 diagnosed with type 2 diabetes in the last 10 years, so 
long as they will receive assessment in tier 3 or equivalent service.
a gastric band is an inflatable band placed around the upper portion of  
the stomach resulting in a reduced stomach capacity above the band. the 
degree of  tightness of  the band can be altered using sterile saline injected 
through a port under the skin, thus potentially inducing satiety (M https:// 
asmbs.org/ patients/ bariatric- surgery- procedures#band).
Roux- en- Y gastric bypass is the most common form of  bypass; a small 
stomach pouch (approximately 30 mL) is made by dividing the top from the 
rest of  the stomach. this is connected to the small bowel (this is the roux 
limb). the roux limb is connected by a y join to the lower part of  the small 
intestine so the stomach acid and enzymes from the bypassed stomach and 
first part of  the small intestine can mix with the food and the remaining 
stomach is left undisturbed. re- routing the stomach alters gut hormones pro-
moting satiety and suppressing hunger, and the small stomach pouch results 
in satiety after small meals. In addition, there may be some malabsorption 
(M https:// asmbs.org/ patients/ bariatric- surgery- procedures#bypass).
Sleeve gastrectomy: approximately 80% of  the stomach is removed, re-
stricting the volume of  food that can be consumed. hormonal changes also 
impact on satiety, hunger, and control of  blood sugar (M https:// asmbs.
org/ patients/ bariatric- surgery- procedures#sleeve).
Long- term follow- up of  morbidities, medication, and nutritional status 
are required (table 21.5); the nature and frequency of  monitoring and type 
of  supplementation required will depend on the procedure the patient has 
undergone.
21 Picot, J., et al. (2009). the clinical effectiveness and cost- effectiveness of  bariatric (weight loss) 
surgery for obesity:  a systematic review and economic evaluation. Health Technol. Assess. 13(41), 
1- 190, 215- 357, iii- iv..
C21.S10
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Table 21.5 recommendations for annual blood test monitoring and 
supplements according to bariatric procedure**
Procedure  Supplement recommendation  Annual blood test monitoring 
recommendations
Gastric band Comprehensive multivitamin 
and mineral supplement 
recommended
Gastric bypass Over the counter (OtC) 




 injections every 
3 months
Calcium and vitamin D 
(additional vitamin D may be 
required)
Iron (start with 200 mg daily 









Calcium and vitamin D
Parathyroid hormone
Zinc and copper
vitamin a (if  long- limb bypass, 
night blindness, or symptoms of  
steatorrhoea present)
Selenium (only measure 








 injections every 
3 months
Calcium and vitamin D 
(additional vitamin D may be 
required).
Iron (start with 200 mg daily 









Calcium and vitamin D
Parathyroid hormone
Zinc, copper, and selenium 
(measure if  concerns about 
possible deficiency)
*annual checks may be unnecessary if  patient is receiving 3- monthly injections of  vitamin B
12
.
**Source: data from O’Kane, M., et al. (2014). BOMSS Guidelines on perioperative and 
postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric 








Many weight loss interventions are delivered within group settings and 
group treatment may be more effective than individual treatment, providing 
social support and cost- effective delivery. Commercial weight- management 
services are delivered within groups and have been shown to be cost- 
effective.22 however, if  these services are offered to patients it is important 
that only programmes which follow best practice guidance are offered and 
that healthcare professionals continue to monitor patients.
Weight loss maintenance
a variety of  lifestyle approaches induce weight loss, but typically when 
interventions stop, weight regain occurs. Keeping lost weight off is a life-
long challenge and different behaviours are needed to keep weight off from 
those to lose weight. those who successfully keep weight off use a var-
iety of  strategies including diet, physical activity (activities of  daily living and 
structured), and a high degree of  self- monitoring. Physical activity has been 
identified as a critical influence protecting against weight regain.
Prevention and public health approaches
the first aim of  public health should be preventing gradual weight gain in 
adults. Simplistic messages about making small changes (such as eating less 
and moving more) ignore the complex nature of  energy balance. Public 
health approaches should target the food, physical activity, and socio- 
economic environments, have a direct influence on behaviours, and support 
clinical interventions and health services. a healthy environment in which 
healthy choices are the easy choices is advocated with action taken across 
the lifecourse.
See E Chapter 18, ‘Obesity prevention’.
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a number of  conditions are associated with obesity.
Down syndrome
Obesity is not inevitable for those with Down syndrome but it may be more 
common. as with other individuals, preventing excess weight gain using diet 
and physical activity is better than managing excess weight gain. those with 
Down syndrome do not need different lifestyle approaches compared with 
others, and similarly to others information needs to be tailored and access-
ible. Sustainable changes to diet and activity to encourage healthier lifestyles 
should be encouraged, within a supportive family environment.
Polycystic ovary syndrome (PCOS)
this condition affects about 5- 10% of  women and is characterized by 
weight gain, hirsuitism (on the face or body), irregular menstrual cycles, 
anovulation, reduced fertility, hormonal abnormalities, and skin changes. 
Women with PCOS have an increased risk of  developing type 2 diabetes 
and heart disease. Losing weight can significantly improve PCOS and reduce 
risks of  co- morbidities. aiming for 5- 10% weight loss is achievable, sustain-
able, and associated with clinical benefits. Modification of  diet and lifestyle 
is first- line treatment.
Prader- Willi syndrome
this rare genetic condition is characterized by reduced growth and muscle 
tone, a constant feeling of  hunger and drive to eat, learning difficulties and 
immature sexual development. Because there is no cure, management 
of  symptoms is key. Maintaining a healthy weight is key but is difficult to 
achieve, as eating behaviours can be obsessive. a care plan will be devel-
oped with healthcare professionals, ideally a paediatric dietitian, and this will 
be monitored and assessed over time. the family should be involved in the 
development of  the care plan.
Further information
M https:// www.downs- syndrome.org.uk/ 
M http:// www.pcos- uk.org.uk/ about- pcos.html
M https:// www.pwsa.co.uk/ 
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